24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham

BJU International

Volumn 118, Issue , 2016, Pages 14-22

  Rukstalis, Daniel ^a   Rashid, Prem ^b   Bogache, William K ^c   Tutrone, Ronald F ^d   Barkin, Jack ^e   Chin, Peter T ^f   Woo, Henry H ^g   Cantwell, Anthony L ^h   Cowan, Barrett E ⁱ   Bolton, Damien M ^j  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b Urology Centre   (Australia)

^c Carolina Urologic Research   (United States)

^d Chesapeake Urology Associates   (United States)

^e Toronto Urology Clinical Study Group   (Canada)

^f Illawarra Urology   (Australia)

^g SYDNEY ADVENTIST HOSPITAL   (Australia)

^h Advanced Urology Institute   (United States)

ⁱ Urology Associates of Denver   (United States)

^j AUSTIN HEALTH   (Australia)

more..

Author keywords

benign prostatic hyperplasia; lower urinary tract symptoms; minimally invasive surgical therapy; sexual function

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; HUMAN; IMPLANT; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE PROCEDURE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATIC URETHRAL LIFT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SHAM PROCEDURE; TRANSURETHRAL RESECTION; URINE FLOW RATE; AUSTRALIA; CANADA; CLINICAL TRIAL; COMPLICATION; CYSTOSCOPY; DOUBLE BLIND PROCEDURE; LOWER URINARY TRACT SYMPTOMS; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; PROSTATIC HYPERPLASIA; SUBURETHRAL SLING; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; AUSTRALIA; CANADA; CROSS-OVER STUDIES; CYSTOSCOPY; DOUBLE-BLIND METHOD; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SUBURETHRAL SLINGS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84995542937     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13666     Document Type: Article

References (29)

1. Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol 2005; 7(Suppl. 4): S3–12
2. van Exel N, Koopmanschap M, McDonnell J et al. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 2006; 49: 92–102
3. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) – focus on the UK. BJU Int 2015; 115: 508–19
4. Roehrborn C. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 2008; 10: 14–25
5. Verhamme K, Dieleman J, Bleumink G, Bosch J, Stricker B, Sturkenboom M. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 2003; 44: 539–45
6. Roehrborn C, McConnell J, Barry M et al. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). American Urological Association Education and Research, Inc., 2003. Available at: https://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm. Accessed October 2016
7. Bachmann A, Tubaro A, Barber N et al. 180-W XPS GreenLight laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European multicentre randomised trial—the GOLIATH study. Eur Urol 2014; 65: 931–42
8. Wroclawski ML, Carneiro A, Amarante RD et al. ‘Button type’ bipolar plasma vaporisation of the prostate compared with standard transurethral resection: a systematic review and meta-analysis of short-term outcome studies. BJU Int 2016; 117: 662–8
9. Wagrell L, Schelin S, Nordling J et al. Feedback microwave thermotherapy versus TURP for clinical BPH – a randomized controlled multicenter study. Urology 2002; 60: 292–9
10. Hill B, Belvill W, Bruskewitz R et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004; 171: 2336–40
11. Bouza C, Lopez T, Magro A, Navalpotro L, Amate J. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urology 2006; 6: 14
12. Dixon CM, Rijo CE, Mynderse LA, Larson TR. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum system: evaluation of acute ablation capabilities in the human prostate. Res Rep Urol 2015; 7: 13–18
13. Woo HH, Chin PT, McNicholas TA et al. Safety and feasibility of the prostatic urethral lift: A novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 2011; 108: 82–8
14. Chin P, Bolton D, Jack G et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012; 79: 5–11
15. Roehrborn C, Gange S, Shore N et al. Multi-center randomized controlled blinded study of the Prostatic Urethral Lift for the treatment of LUTS associated with prostate enlargement due to BPH: the LIFT study. J Urol 2013; 190: 2161–7
16. Cantwell A, Bogache W, Richardson S et al. Multi-center prospective crossover study of the Prostatic Urethral Lift for the treatment of LUTS secondary to BPH. BJU Int 2014; 113: 615–22
17. Barkin J, Giddens J, Incze P et al. UroLift system for relief of prostate obstruction under local anesthesia. Can J Urol 2012; 19: 6217–22
18. Shore N, Freedman S, Gange S et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol 2014; 21: 7094–101
19. McNicholas T, Woo H, Chin P et al. Minimally invasive Prostatic Urethral Lift: surgical technique and multinational experience. Eur Urol 2013; 64: 292–9
20. Roehrborn C, Rukstalis D, Barkin J et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 2015; 22: 7772–82
21. Roehrborn C, Gange S, Shore N et al. Durability of the Prostatic Urethral Lift: 2-year results of the L.I.F.T. study. Urol Pract 2015; 2: 26–32
22. Sonksen J, Barber N, Speakman M et al. Prospective, randomized, multinational study of the prostatic urethral lift versus transurethral resection of the prostate: 12-month results of the BPH6 Study. Eur Urol 2015; 68: 643–52
23. McVary K, Gange S, Shore N et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of Prostatic Urethral Lift. J Sex Med 2014; 11: 279–87
24. Woo H, Bolton D, Laborde E et al. Preservation of sexual function with the Prostatic Urethral Lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 2012; 9: 568–75
25. National Institute for Health and Care Excellence (NICE). UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia. Medical Technologies Guidance (MTG26). London: NICE, 2015. Available at: https://www.nice.org.uk/guidance/mtg26?unlid. Accessed October 2016
26. Welliver C, Kottwitz M, Feustel P, McVary K. Clinically and statistically significant changes seen in sham surgery arms of randomized, controlled benign prostatic hyperplasia surgery trials. J Urol 2015; 193(4S): e93
27. Magistro G, Stief C, Gratzke C. New intraprostatic injectables and prostatic urethral life for male LUTS. Nat. Rev. Urol 2015; 12: 461–71
28. Becher E, McVary K. Surgical procedures for BPH/LUTS: Impact on Male Sexual Health. Sex Med Rev 2014; 2: 47–55
29. Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, Gontero P. Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men's ejaculatory function: Time for a bespoke approach? Int J Urol 2016; 23: 22–35